What's new?

Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-Stage Healthcare VC Fund in Europe

European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform PARIS, France – October 19,¬ 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest earl...

Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform

Financing led by Casdin Capital, Sofinnova Partners - initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing established with groundbreaking research from Institut Curie and Memorial Sloan Kettering Paris, France, June 16, 2021 – Mnemo...

EnginZyme awarded as Technology Pioneer 2021 by World Economic Forum

STOCKHOLM, 15 June 2021 – EnginZyme, enabling the future of sustainable chemical production, announces that the World Economic Forum has selected it as one of the 2021 Technology Pioneers. This prestigious recognition highlights the company’s innovations that address the challenges of the chemical industry in the 2...

Medtech Accelerator Sofinnova MD Start III Launches a Call for early stage Medical Device Projects

PARIS, France – June 8, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its medtech accelerator, Sofinnova MD Start III, is launching a call for early-stage projects. Sofinnova MD Start III is part of the Sofinnova platform of f...

GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment

Paris, France, May 25, 2021, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the highly...

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

PARIS, France, May 24, 2021 – 6:30 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces positive phase 2b clinical induction and p...

Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output

AMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This ...

Protera Appoints Novozymes Executive Thomas Videbaek As Chair of the Board of Directors and Non-Executive Board Member

SANTIAGO, CHILE and PARIS, FRANCE / ACCESSWIRE / April 6, 2021 / Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced today it has appointed Novozymes senior executive Thomas Videbaek as Chair of the Board of Directors and non-exe...

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

- QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) - QR-421a observed to be well tolerated with no serious adverse events reported - Two pivotal Phase 2/3 trials are expected to start by the end of ...

Avantium secures new offtake contracts for planned FDCA flagship plant

Final Investment Decision Progress Update   AMSTERDAM, 24 March 2021, 07:00 CET – Avantium N.V., a leading technology company in renewable chemistry, announces that its subsidiary Avantium Renewable Polymers (“Avantium RNP”) has signed two additional conditional offtake agreements for the supply of PEF resin to man...

Inotrem Bolsters Leadership Team With the Appointment of Sven Zimmermann as New CEO

March 24, 2021 03:00 AM Eastern Daylight Time   PARIS--(BUSINESS WIRE)--Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th, 2021. Sven bri...

1 2 3 4 5 ... 187